MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study

Benzer Materyaller

• Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
  Yazar:: Gordon, Murray B, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
  Yazar:: Nachtigall, Lisa B, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial
  Yazar:: Biermasz, Nienke, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
  Yazar:: Nachtigall, Lisa B, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly
  Yazar:: Samson, Susan Leanne, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)